Leukemia

Papers
(The H4-Index of Leukemia is 49. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-11-01 to 2025-11-01.)
ArticleCitations
Quantifying measurable residual disease correctly2908
Targeting CERS6-AS1/FGFR1 axis as synthetic vulnerability to constrain stromal cells supported proliferation in Mantle cell lymphoma2657
Impact of somatic gene mutations on the risk of thrombosis in myelofibrosis186
Correction: Frequent HLA-DR loss on hematopoietic stem progenitor cells in patients with cyclosporine-dependent aplastic anemia carrying HLA-DR15166
Genomic DNA-based measurable residual disease monitoring in pediatric acute myeloid leukemia: unselected consecutive cohort study153
Publisher Correction: Bortezomib-based induction, high-dose melphalan and lenalidomide maintenance in myeloma up to 70 years of age121
Co-targeting leukemia-initiating cells and leukemia bulk leads to disease eradication105
The 5th edition of the WHO classification of haematolymphoid tumors: comments from the Groupe Francophone de Cytogénétique Hématologique (GFCH)104
MCL1 as a therapeutic vulnerability in Burkitt lymphoma100
Does older age justify chlorambucil control arms for chronic lymphocytic leukemia clinical trials: a SEER-Medicare analysis97
CD36 cell surface expression as a surrogate marker to identify ABL/JAK-class kinase fusions in pediatric BCP-ALL94
Retraction Note: SAR650984 directly induces multiple myeloma cell death via lysosomal-associated and apoptotic pathways, which is further enhanced by pomalidomide92
The JAK1/2 inhibitor ruxolitinib in patients with COVID-19 triggered hyperinflammation: the RuxCoFlam trial88
Anagrelide and idarubicin combination induces GSDME-mediated pyroptosis as a potential therapy for high-PDE3A acute myeloid leukemia88
Nucleic acid therapeutics as differentiation agents for myeloid leukemias86
Characterization of myeloproliferative neoplasms based on genetics only and prognostication of transformation to blast phase86
Real life evaluation of AlphaMissense predictions in hematological malignancies76
Co-targeting of the thymic stromal lymphopoietin receptor to decrease immunotherapeutic resistance in CRLF2-rearranged Ph-like and Down syndrome acute lymphoblastic leukemia71
Comparison between measurable residual disease relapse and morphologic relapse in acute myeloid leukemia and high-grade myeloid neoplasms70
Combining LSD1 and JAK-STAT inhibition targets Down syndrome-associated myeloid leukemia at its core69
Invasive fungal diseases impact on outcome of childhood ALL – an analysis of the international trial AIEOP-BFM ALL 200968
Mutant IL7R collaborates with MYC to induce T-cell acute lymphoblastic leukemia68
Chronic lymphocytic leukemia patient-derived xenografts recapitulate clonal evolution to Richter transformation68
The complex karyotype in hematological malignancies: a comprehensive overview by the Francophone Group of Hematological Cytogenetics (GFCH)68
Analysis and therapeutic targeting of the EP300 and CREBBP acetyltransferases in anaplastic large cell lymphoma and Hodgkin lymphoma67
Cohesin mutations in acute myeloid leukemia66
Molecular determinants of outcomes in relapsed or refractory mantle cell lymphoma treated with ibrutinib or temsirolimus in the MCL3001 (RAY) trial66
The potential of cell-free DNA to reveal the molecular profiles of Langerhans cell histiocytosis and Erdheim–Chester disease in adults66
Diverse mechanisms of leukemogenesis associated with PAX5 germline mutation61
Rheumatoid arthritis and the risk of hematologic malignancies: a nationwide cohort study59
Bidirectional anti-tumor and immunological strategies by targeting GARP–TGF-β axis in adult T-cell leukemia/lymphoma59
Novel causative variants of VEXAS in UBA1 detected through whole genome transcriptome sequencing in a large cohort of hematological malignancies58
Single-cell analysis of immune recognition in chronic myeloid leukemia patients following tyrosine kinase inhibitor discontinuation58
Somatic TP53 single nucleotide variants, indels and copy number alterations in chronic myelomonocytic leukemia (CMML)58
Allogeneic Hematopoietic Cell Transplantation in Advanced Systemic Mastocytosis: A retrospective analysis of the DRST and GREM registries57
Clonal medicine targeting DNA damage response eradicates leukemia55
DDX41 coordinates RNA splicing and transcriptional elongation to prevent DNA replication stress in hematopoietic cells55
Characterisation and prognostic impact Of ZRSR2 mutations in myeloid neoplasms55
Clonal hematopoiesis and its impact on the aging osteo-hematopoietic niche54
Patient-reported outcomes in Philadelphia chromosome-positive acute lymphoblastic leukemia patients treated with ponatinib or imatinib: results from the PhALLCON trial53
Recommendations for the management of COVID-19 in patients with haematological malignancies or haematopoietic cell transplantation, from the 2021 European Conference on Infections in Leukaemia (ECIL 953
Outcomes of first therapy after CD19-CAR-T treatment failure in large B-cell lymphoma52
ctDNA dynamics demonstrates rapid treatment response to tafasitamab + R-CHOP +/− lenalidomide and predicts outcome in diffuse large B-cell lymphoma: results from the phase 1b First-MIND study52
Real-time genomic characterization of pediatric acute leukemia using adaptive sampling52
Essential role of Dhx16-mediated ribosome assembly in maintenance of hematopoietic stem cells51
Correction to: Histone deacetylase (HDAC) inhibitor ACY241 enhances anti-tumor activities of antigen-specific central memory cytotoxic T lymphocytes against multiple myeloma and solid tumors50
An MDM2 degrader for treatment of acute leukemias50
Correction: Mitochondrial regulation of GPX4 inhibition–mediated ferroptosis in acute myeloid leukemia49
Combining lenalidomide with erythropoiesis stimulating agents: a party of one49
0.4578709602356